Results 161 to 170 of about 223,681 (205)
Some of the next articles are maybe not open access.
Cardiology Clinics, 2015
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes.
Kevin C, Maki +2 more
openaire +3 more sources
A statin is first-line drug therapy for dyslipidemia. Clinical trial data suggest there is an increase in the incidence of new-onset type 2 diabetes mellitus with statin use. The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes.
Kevin C, Maki +2 more
openaire +3 more sources
The American Journal of Cardiology, 2014
The term statin intolerance refers to an inability to use statins because of muscle symptoms or elevated creatine kinase, and the major diagnostic challenge is to unambiguously link these to statin use. Roughly 5% to 10% of statin users develop statin intolerance, and because statin use is expected to increase--especially after recent updated ...
openaire +2 more sources
The term statin intolerance refers to an inability to use statins because of muscle symptoms or elevated creatine kinase, and the major diagnostic challenge is to unambiguously link these to statin use. Roughly 5% to 10% of statin users develop statin intolerance, and because statin use is expected to increase--especially after recent updated ...
openaire +2 more sources
Outcomes of Statin Myopathy After Statin Withdrawal
Journal of Clinical Neuromuscular Disease, 2013Abstract Objective: To study the outcomes of statin myopathy after statin withdrawal. Methods: Sixty-nine patients with mild statin myopathy were studied by chart review. Results: Mean age at presentation was 62.1 years.
Ryan, Armour, Lan, Zhou
openaire +2 more sources
Current Pharmaceutical Design, 2012
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are primarily used to treat dyslipidemia. Yet, these medications have a number of additional important pleiotropic properties that confer patient benefit in terms of reduced cardiovascular morbidity.
openaire +2 more sources
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are primarily used to treat dyslipidemia. Yet, these medications have a number of additional important pleiotropic properties that confer patient benefit in terms of reduced cardiovascular morbidity.
openaire +2 more sources
[Statin intolerance-Statin tolerance].
Innere Medizin (Heidelberg, Germany), 2023Statins are the first-line treatment for reducing low-density lipoprotein (LDL) cholesterol levels, because the evidence regarding safety, tolerability, and reduction of cardiovascular morbidity and mortality is very good. For combination treatment several options are available.
openaire +1 more source
Progress in Neurobiology, 2009
Clinical trials report that the class of drugs known as statins may be neuroprotective in Alzheimer's and Parkinson's disease, and further trials are currently underway to test whether these drugs are also beneficial in multiple sclerosis and acute stroke treatment.
van der Most, Peter J. +4 more
openaire +1 more source
Clinical trials report that the class of drugs known as statins may be neuroprotective in Alzheimer's and Parkinson's disease, and further trials are currently underway to test whether these drugs are also beneficial in multiple sclerosis and acute stroke treatment.
van der Most, Peter J. +4 more
openaire +1 more source
New England Journal of Medicine, 2014
Jeffrey M, Drazen, Annetine C, Gelijns
openaire +2 more sources
Jeffrey M, Drazen, Annetine C, Gelijns
openaire +2 more sources